10-Q: Twist Bioscience Reports 25% Revenue Growth in Q2 2024, Gross Margin Expands to 41%

Twist Bioscience saw a 25% increase in revenue year-over-year, reaching $75.3 million in the second quarter of 2024, driven by strong growth in NGS tools and synthetic genes.

Summary

• Twist Bioscience reported a 25% increase in revenue for the three months ended March 31, 2024, reaching $75.3 million, compared to $60.2 million for the same period in 2023.
• The company's gross profit margin improved significantly to 41% from 31% year-over-year.
• The number of genes shipped increased by 27% to 193,000 in the quarter.
• Net loss for the quarter was $45.5 million, an improvement from the $59.2 million loss in the same period last year.
• The company's net cash used in operating activities decreased to $42.4 million for the six months ended March 31, 2024, compared to $98.4 million for the same period in 2023.
• As of March 31, 2024, Twist Bioscience had $243.3 million in cash and cash equivalents and $50.0 million in short-term investments.
• The company's accumulated deficit as of March 31, 2024, was $1,121.7 million.

Sentiment

Score: 7

Explanation: The document shows strong revenue growth and improved gross margins, which are positive indicators. However, the company is still operating at a loss and has a material weakness in internal controls, which tempers the overall sentiment. The reduction in cash burn is a positive sign.

Positives

• The company experienced strong revenue growth of 25% year-over-year.
• Gross margin improved significantly, indicating better cost management and pricing strategies.
• The number of genes shipped increased substantially, demonstrating increased production and demand.
• The company reduced its net loss compared to the same period last year.
• Cash used in operating activities decreased significantly, showing improved operational efficiency.
• The company has a strong cash position with $293.3 million in cash, cash equivalents, and short-term investments.
• NGS tools and synthetic genes showed strong revenue growth.

Negatives

• The company continues to operate at a net loss, with a loss of $45.5 million for the quarter.
• The company has an accumulated deficit of $1,121.7 million.
• The company is still reliant on external funding to support operations.
• There is a material weakness in internal control over financial reporting.

Risks

• The company's ability to achieve profitability depends on the success of existing products and the development of new products.
• The company faces risks related to market acceptance of its products, competition, and the ability to manage growth.
• The company's ability to obtain additional financing is uncertain.
• The company has a material weakness in internal control over financial reporting.
• The company is subject to legal proceedings, including a securities class action lawsuit and a derivative action.

Future Outlook

The company expects to continue investing in product development, manufacturing, and sales and marketing. The company's ability to achieve profitability will depend on the success of its existing products and the development and commercialization of additional products, including Express Genes, and leveraging its manufacturing facility in Wilsonville, Oregon.

Management Comments

• Management believes that the company's cash and cash equivalents and short-term investments will be sufficient to fund operations for at least one year from the issuance of these consolidated financial statements.
• Management intends to vigorously defend themselves against the claims asserted in the securities class action lawsuit and derivative action.

Industry Context

The company's growth in NGS tools and synthetic genes reflects the increasing demand for these products in the broader synthetic biology and genomics industries. The company's focus on expanding its manufacturing capabilities and product portfolio aligns with the industry trend of scaling up production and diversifying product offerings.

Comparison to Industry Standards

• Twist Bioscience's 25% revenue growth is strong compared to some of its peers in the synthetic biology space, although direct comparisons are difficult due to varying business models and product focuses.
• Companies like Ginkgo Bioworks and Amyris also operate in the synthetic biology sector, but their financial results and growth trajectories differ significantly from Twist.
• Twist's focus on DNA synthesis and its silicon-based platform differentiates it from companies that focus on other aspects of synthetic biology, such as fermentation or strain engineering.
• The gross margin improvement to 41% is a positive sign, indicating that Twist is becoming more efficient in its operations, which is a key metric for companies in this sector.
• The company's continued net losses are not uncommon for growth-stage companies in the biotech industry, but the reduction in cash burn is a positive trend.

Management Changes

Legal Proceedings

• The company is involved in a securities class action lawsuit and a shareholder derivative suit.
• The securities class action lawsuit alleges violations of federal securities laws based on allegations made in a report concerning the company's DNA chip technology and accounting practices.
• The derivative action seeks to recover damages to the company arising from the securities class action lawsuit.

Related Party Transactions

• The company purchased raw materials from a related party in the amount of $1.5 million and $2.8 million for the three and six months ended March 31, 2024, respectively.
• The company had revenues from a related party in the amount of $3.2 million and $5.6 million for the three and six months ended March 31, 2024, respectively.

Stakeholder Impact

• Shareholders are impacted by the company's financial performance, including revenue growth, gross margin, and net loss.
• Employees are impacted by the company's restructuring plan and changes in personnel costs.
• Customers are impacted by the company's product offerings and turnaround times.
• Suppliers are impacted by the company's purchasing activities and related party transactions.
• Creditors are impacted by the company's financial stability and ability to meet its obligations.

Next Steps

• The company will continue to enhance its overall control environment and remediate the identified material weakness in internal control over financial reporting.
• The company will continue to invest in product development, manufacturing, and sales and marketing.
• The company will focus on leveraging its manufacturing facility in Wilsonville, Oregon.

Key Dates

Keywords

synthetic biology, DNA synthesis, NGS tools, synthetic genes, antibody discovery, genomics, biologic drugs, data storage, revenue growth, gross margin, financial results